Icatibant Glenmark

Icatibant, the active ingredient in Icatibant Glenmark, is a bradykinin B2 receptor antagonist presented as a 30 mg per 0.3 mL prefilled syringe for subcutaneous injection. It is indicated for the treatment of acute attacks of hereditary angioedema, reducing swelling and improving airway patency in affected individuals.

GNH USA supplies Icatibant Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this specialty injectable for qualified healthcare providers through regulated distribution channels and strict quality assurance.

Icatibant acts on the bradykinin pathway and is indicated for hereditary angioedema. - Hereditary angioedema (C1‑inhibitor deficiency): reduces swelling during acute attacks. - Hereditary angioedema (normal C1‑inhibitor): alleviates edema in acute episodes.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: localized redness around the injection area. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache following administration.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure after injection. - Angioedema at injection site: unexpected swelling despite therapeutic intent.

When using Icatibant, several precautions should be observed to ensure safe administration. - Assess patient history: confirm diagnosis of hereditary angioedema before use. - Monitor for hypersensitivity: observe patient after injection for signs of allergic reaction. - Avoid in patients with known hypersensitivity to icatibant or excipients. - Use with caution in patients on ACE inhibitors: increased bradykinin levels may raise risk of angioedema. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, heightening risk of angioedema. - Concurrent use of other bradykinin B2 antagonists: additive pharmacologic effects not studied.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may influence frequency of hereditary angioedema attacks. - Diuretics: monitor blood pressure and volume status. - Immunosuppressants: observe for increased infection risk.